SCHEMBL24378461

SCHEMBL24378461

Cc1cccc(-c2nc(C)n(CCN(C)C)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.42
KMT2A Q03164 3/20 0.42
RAD52 P43351 1/20 0.42
RAB9A P51151 6/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
NPC1 O15118 5/20 0.39
L3MBTL1 Q9Y468 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
TDP1 Q9NUW8 4/20 0.39
MAPK1 P28482 3/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27009232 0.84 RAD52 (0.39) TDP2KMT2ARAD52RAB9AKDM4E
SCHEMBL24378458 0.72 TLR8 (0.51) KMT2ARAD52RAB9AKDM4EALDH1A1
SCHEMBL14500119 0.69 ROCK1 (0.47) KMT2AKDM4EALDH1A1POLBHPGD
SCHEMBL19196304 0.68 NR1H3 (0.51) KMT2ARAB9AKDM4EALDH1A1POLB
SCHEMBL11553898 0.68 TDP2 (0.46) TDP2KMT2ARAB9AKDM4EALDH1A1
SCHEMBL29968811 0.68 KDM4E (0.43) KMT2ARAD52KDM4EALDH1A1POLB
SCHEMBL3766697 0.67 RAB9A (0.73) KMT2ARAB9APOLBHPGDNPC1
SCHEMBL14736606 0.67 NR1H3 (0.53) KMT2ARAB9AKDM4EALDH1A1POLB
SCHEMBL7921132 0.67 NR1H3 (0.53) KMT2ARAB9AKDM4EALDH1A1POLB
SCHEMBL24378498 0.67 KDM4E (0.49) KMT2ARAD52RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 TDP2 684/4885KMT2A 4126/4885RAD52 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.